----

----

**FORM      10-QSB**

| x      | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF                THE SECURITIES EXCHANGE ACT OF 1934 For                the quarter ended **April                30, 2006**         |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                |
|  ̈ | TRANSITION                REPORT UNDER SECTION 13 OR 15 (d)OF                THE SECURITIES EXCHANGE ACT OF 1934 For                the transition period from                _______to_______ |

**333-57946**

**INHIBITON      THERAPEUTICS, INC.**

| **Nevada**                                     | **88-0448626**                     |
|------------------------------------------------|------------------------------------|
| (State                or other jurisdiction of | (IRS                Employer       |
| incorporation                or organization)  | Identification                No.) |

**7315      East Peakview Avenue**

**Englewood,      Colorado 80111**

**(303)      796-8940**

----

----

**INHIBITON      THERAPEUTICS, INC.**

**(A      Development Stage Company)**

**Index      to Financial Statements**

**(Unaudited)**

|                                                                              |                                                                                               | **Page** |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------|
|                                                                              |                                                                                               |     |
| Balance                Sheet at April 30, 2006                                    | F-2                                                                                                |
|                                                                              |                                                                                               |     |
| Statement                of Operations for the three months ended April 30, 2006, |                                                                                               |
|                                                                              | three                months ended April 30, 2005, and from May 11, 2004 (Inception)                |     |
|                                                                              | through                April 30, 2006                                                              | F-3      |
|                                                                              |                                                                                               |     |
| Statement                of Changes in Shareholders' Deficit for the period from  |                                                                                               |
|                                                                              | May                11, 2004 (Inception) through April 30, 2006                                     | F-4      |
|                                                                              |                                                                                               |     |
| Statement                of Cash Flows for the three months ended April 30, 2006, |                                                                                               |
|                                                                              | three                months ended April 30, 2005, and from May 11, 2004                (Inception) |     |
|                                                                              | through                April 30, 2006                                                              | F-5      |
|                                                                              |                                                                                               |     |
| Notes                to Financial Statements                                      | F-6                                                                                                |

----

|                **INHIBITON                THERAPEUTICS, INC.****(A                Development Stage Company)****Condensed                Balance Sheet****(Unaudited)****April                30, 2006** |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                                                                                                          |   |
| **Assets**                                                                                                                                                                                                    |   |
| Cash                                                                                                                                                                                                          |   | $ | 300 |   |
|                                                                                                                                                                                                          |   |   |   |   |
|  Total                assets                                                                                                                                                                             |   | $ | 300 |   |
|                                                                                                                                                                                                          |   |   |   |   |
| **Liabilities                and Shareholders’ Deficit**                                                                                                                                                |
| Current                liabilities:                                                                                                                                                                           |   |   |   |   |
| Accounts                and notes payable:                                                                                                                                                                    |   |   |   |   |
| Accounts                payable, related party (Note 2)                                                                                                                                                       |   | $ | 162,125 |   |
| Accounts                payable, other                                                                                                                                                                        |   |   | 75,404 |   |
| Notes                payable, related party (Note 2)                                                                                                                                                          |   |   | 447,842 |   |
| Notes                payable, other                                                                                                                                                                           |   |   | 30,000 |   |
| Convertible                notes payable (Note 3)                                                                                                                                                             |   |   | 225,000 |   |
| Accrued                interest payable:                                                                                                                                                                      |   |   |   |   |
| Notes                payable, related party (Note 2)                                                                                                                                                          |   |   | 11,813 |   |
| Notes                payable, other                                                                                                                                                                           |   |   | 2,117 |   |
| Convertible                notes (Note 3)                                                                                                                                                                     |   |   | 34,861 |   |
|                                                                                                                                                                                                          |   |   |   |   |
|  Total                current liabilities                                                                                                                                                                |   |   | 989,162 |   |
|                                                                                                                                                                                                          |   |   |   |   |
| Commitments                and contingencies                                                                                                                                                                  |   |   | — |   |
|                                                                                                                                                                                                          |   |   |   |   |
| Shareholders’                deficit:                                                                                                                                                                   |   |   |   |   |
| Preferred                stock, $.01 par value. 100,000 shares authorized,                                                                                                                                    |   |   |   |   |
| -0-                shares issued and outstanding                                                                                                                                                              |   |   | — |   |
| Common                stock, $.001 par value. 50,000,000 shares authorized,                                                                                                                                   |   |   |   |   |
| 13,451,000                shares issued and outstanding                                                                                                                                                       |   |   | 13,451 |   |
| Additional                paid-in capital                                                                                                                                                                     |   |   | 323,793 |   |
| Deficit                accumulated during the development stage                                                                                                                                               |   |   | (1,326,106 | ) |
|                                                                                                                                                                                                          |   |   |   |   |
|  Total                shareholders' deficit                                                                                                                                                              |   |   | (988,862 | ) |
|                                                                                                                                                                                                          |   |   |   |   |
|  Total                liabilities and shareholders' deficit                                                                                                                                              |   | $ | 300 |   |

----

|                **INHIBITON                THERAPEUTICS, INC.****(A                Development Stage Company)****Condensed                Statements of Operations****(Unaudited)**  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                          |   |    |   |   |   | **May                11, 2004** |   |
|                                                                                                                                                                                          |   |  **Three                months** |   | **Three                months** |   | **(Inception)** |   |
|                                                                                                                                                                                          |   |  **Ended** |   | **Ended** |   | **Through** |   |
|                                                                                                                                                                                          |   |  **April                30,** |   | **April                30,** |   | **April                30,** |   |
|                                                                                                                                                                                          |   |  **2006** |   | **2005** |   | **2006** |   |
| Operating                costs and expenses:                                                                                                                                                  |   |   |  |   |   |  |   |   |   |   |
| Research                and development                                                                                                                                                       |   | $ | 75,000 |   | $ | 75,000 |   | $ | 525,000 |   |
| Selling,                general and administrative expenses                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |
| Related                party (Note 2)                                                                                                                                                         |   |   | 32,250 |   |   | 32,250 |   |   | 556,925 |   |
| Other                (net of stock based compensation)                                                                                                                                        |   |   | 4,407 |   |   | 76,915 |   |   | 185,149 |   |
| Stock                based compensation                                                                                                                                                       |   |   | — |   |   | — |   |   | 1,000 |   |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Total                operating costs and expenses                                                                                                                                             |   |   | (111,657 | ) |   | (184,165 | ) |   | (1,268,074 | ) |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Interest                income (Note 3)                                                                                                                                                       |   |   | — |   |   | 2,244 |   |   | 80,183 |   |
| Interest                expense (Notes 2, 3)                                                                                                                                                  |   |   | (15,640 | ) |   | (47,061 | ) |   | (138,215 | ) |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Loss                before income taxes                                                                                                                                                       |   |   | (127,297 | ) |   | (228,982 | ) |   | (1,326,106 | ) |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Income                tax provision (Note 4)                                                                                                                                                  |   |   | — |   |   | — |   |   | — |   |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                                                                                                                                                       |   | $ | (127,297 | ) | $ | (228,982 | ) | $ | (1,326,106 | ) |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Basic                and diluted loss per share                                                                                                                                               |   | $ | (0.01 | ) | $ | (1.21 | ) |   |   |   |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Weighted                average common shares outstanding                                                                                                                                     |   |   | 13,451,000 |   |   | 189,765 |   |   |   |   |

----

|                **INHIBITON                THERAPEUTICS, INC.****(A                Development Stage Company)****Condensed                Statement of Changes in Shareholders’ Deficit****(Unaudited)**  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   | **Deficit** |   |   |   |
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   | **accumulated** |   |   |   |
|                                                                                                                                                                                                                     |   | **Common                Stock** |   | **Additional** |   | **during                the** |   |   |   |
|                                                                                                                                                                                                                     |   | **Shares** |   | **Par                value** |   | **paid-in                capital** |   | **development                stage** |   | **Total** |   |
| Balance                at May 11, 2004                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Inception                date                                                                                                                                                                                            |   |   | — |   | $ | — |   | $ | — |   | $ | — |   | $ | — |   |
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| October                2004 and January 2005,                                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| sale                of common stock                                                                                                                                                                                      |   |   | 9,555,100 |   |   | 9,555 |   |   | 269,945 |   |   | — |   |   | 279,500 |   |
| October                2004, issuance of common stock                                                                                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| for                debt issue costs                                                                                                                                                                                      |   |   | 963,000 |   |   | 963 |   |   | (63 | ) |   | — |   |   | 900 |   |
| December                2004, issuance of common stock                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| for                services                                                                                                                                                                                              |   |   | 107,000 |   |   | 107 |   |   | 893 |   |   | — |   |   | 1,000 |   |
| January                2005, conversion of notes payable to                                                                                                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| common                stock                                                                                                                                                                                              |   |   | 74,900 |   |   | 75 |   |   | 625 |   |   | — |   |   | 700 |   |
| Net                loss                                                                                                                                                                                                  |   |   | — |   |   | — |   |   | — |   |   | (534,619 | ) |   | (534,619 | ) |
| Balance                at January 31, 2005                                                                                                                                                                               |   |   | 10,700,000 |   |   | 10,700 |   |   | 271,400 |   |   | (534,619 | ) |   | (252,519 | ) |
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| February                2005 and March 2005,                                                                                                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| sale                of common stock                                                                                                                                                                                      |   |   | 428,000 |   |   | 428 |   |   | 99,572 |   |   | — |   |   | 100,000 |   |
| May                2005 Reverse acquisition of Organic                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Soils.com,                Inc. (Note 1)                                                                                                                                                                                  |   |   | 2,323,000 |   |   | 2,323 |   |   | (47,179 | ) |   |   |   |   | (44,856 | ) |
| Net                loss                                                                                                                                                                                                  |   |   | — |   |   | — |   |   | — |   |   | (664,190 | ) |   | (664,190 | ) |
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance                at January 31, 2006                                                                                                                                                                               |   |   | 13,451,000 |   |   | 13,451 |   |   | 323,793 |   |   | (1,198,809 | ) |   | (861,565 | ) |
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                                                                                                                                                                                  |   |   | — |   |   | — |   |   | — |   |   | (127,297 | ) |   | (127,297 | ) |
|                                                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance                at April 30, 2006                                                                                                                                                                                 |   |   | 13,451,000 |   | $ | 13,451 |   | $ | 323,793 |   | $ | (1,326,106 | ) | $ | (988,862 | ) |

----

|                **INHIBITON                THERAPEUTICS, INC.****(A                Development Stage Company)****Condensed                Statements of Cash Flows****(Unaudited)**  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                          |   |    |   |   |   | **May                11, 2004** |   |
|                                                                                                                                                                                          |   |  **Three                months** |   | **Three                Months** |   | **(Inception)** |   |
|                                                                                                                                                                                          |   |  **Ended** |   | **Ended** |   | **Through** |   |
|                                                                                                                                                                                          |   |  **April                30,** |   | **April                30,** |   | **April                30,** |   |
|                                                                                                                                                                                          |   |  **2006** |   | **2005** |   | **2006** |   |
| Cash                flows from operating activities:                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                                                                                                                                                       |   | $ | (127,297 | ) | $ | (228,982 | ) | $ | (1,326,106 | ) |
| Adjustments                to reconcile net loss to net cash                                                                                                                                  |   |   |   |   |   |   |   |   |   |   |
| used                by operating activities:                                                                                                                                                  |   |   |   |   |   |   |   |   |   |   |
| Stock                based compensation                                                                                                                                                       |   |   | — |   |   | — |   |   | 1,000 |   |
| Changes                in operating assets and liabilities:                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |
| Prepaid                expense                                                                                                                                                                |   |   | — |   |   | (50,000 | ) |   | — |   |
| Accounts                payable                                                                                                                                                               |   |   | 16,460 |   |   | (99,353 | ) |   | 75,405 |   |
| Related                party payables (Note 2)                                                                                                                                                |   |   | 32,250 |   |   | (32,250 | ) |   | 162,125 |   |
| Accrued                expenses                                                                                                                                                               |   |   | 11,858 |   |   | 82,863 |   |   | 48,791 |   |
| Net                cash used in                                                                                                                                                               |   |   |  |   |   |   |   |   |   |   |
|  operating                activities                                                                                                                                                     |   |   | (66,729 | ) |   | (327,722 | ) |   | (1,038,785 | ) |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Cash                flows from investing activities:                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Investment                in Inhibitex Therapeutics, Inc.                                                                                                                                     |   |   | — |   |   | 208 |   |   | (44,856 | ) |
| Net                cash used in                                                                                                                                                               |   |   |   |   |   |   |   |   |   |   |
|  investing                activities                                                                                                                                                     |   |   | — |   |   | 208 |   |   | (44,856 | ) |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Cash                flows from financing activities:                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Proceeds                from related party notes payable, net                                                                                                                                 |   |   | 66,282 |   |   | 40,467 |   |   | 449,441 |   |
| Proceeds                from notes payable, other                                                                                                                                             |   |   | — |   |   | 30,000 |   |   | 30,000 |   |
| Proceeds                from convertible promissory note                                                                                                                                      |   |   | — |   |   | (38,721 | ) |   | 225,000 |   |
| Proceeds                from issuance of common stock                                                                                                                                         |   |   | — |   |   | 100,000 |   |   | 379,500 |   |
| Net                cash provided by                                                                                                                                                           |   |   |  |   |   |   |   |   |   |   |
|  financing                activities                                                                                                                                                     |   |   | 66,282 |   |   | 131,746 |   |   | 1,083,941 |   |
|                                                                                                                                                                                          |   |   |  |   |   |   |   |   |   |   |
| Net                change in cash and                                                                                                                                                         |   |   |  |   |   |   |   |   |   |   |
|  cash                equivalents                                                                                                                                                         |   |   | (447 | ) |   | (195,768 | ) |   | 300 |   |
|                                                                                                                                                                                          |   |   |  |   |   |   |   |   |   |   |
| Cash                and cash equivalents:                                                                                                                                                     |   |   |  |   |   |   |   |   |   |   |
| Beginning                of period                                                                                                                                                            |   |   | 747 |   |   | 213,727 |   |   | — |   |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| End                of period                                                                                                                                                                  |   | $ | 300 |   | $ | 17,959 |   | $ | 300 |   |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Supplemental                disclosure of cash flow information:                                                                                                                              |   |   |   |   |   |   |   |   |   |   |
| Cash                paid during the period for:                                                                                                                                               |   |   |   |   |   |   |   |   |   |   |
| Income                taxes                                                                                                                                                                   |   | $ | — |   | $ | — |   | $ | — |   |
| Interest                                                                                                                                                                                      |   | $ | 36,954 |   | $ | 5,438 |   | $ | 42,392 |   |
|                                                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |
| Noncash                financing transactions:                                                                                                                                                |   |   |   |   |   |   |   |   |   |   |
| Notes                payable converted to stock                                                                                                                                               |   | $ | — |   | $ | — |   | $ | 700 |   |
| Stock                issued in exchange for debt issue costs                                                                                                                                  |   | $ | — |   | $ | — |   | $ | 900 |   |

----

**INHIBITON                THERAPEUTICS, INC.**

**(A                Development Stage Company)**

**Notes                to Condensed Financial Statements**

**(Unaudited)**

**Note        1: **
**Basis        of presentation**

**Reorganization**

**Derivative        Instruments**

----

**INHIBITON              THERAPEUTICS, INC.**

**(A              Development Stage Company)**

**Notes              to Condensed Financial Statements**

**(Unaudited)**

**Note      2: **
**Related      Party**

----

**INHIBITON          THERAPEUTICS, INC.**

**(A          Development Stage Company)**

**Notes          to Condensed Financial Statements**

**(Unaudited)**

**Note        3: **
**Convertible        Notes Payable**

----

**Note      4: **
**Income      Tax**

----

**Item      2. Plan of Operation**

----

**.**

**Item      3. Controls and Procedures**

**PART      II - OTHER INFORMATION**

**Item      1. Legal Proceedings**

**Item      2. Unregistered Sales of Equity Securities**

**Item      3. Defaults upon Senior Securities**

**Item      4. Submission of Matters to a Vote of Security Holders**

**Item      5. Other Information**

----

**Item      6. Exhibits**

| **Exhibits:** |                                                                                                      |
|---------------|-----------------------------------------------------------------------------------------------------------|
| 31.1          | CEO                Certification pursuant to Section 302 of the Sarbanes-Oxley Act of                2002 |
| 32.1          | CEO                Certification pursuant to Section 906 of the Sarbanes-Oxley Act of                2002 |

----

|   | **INHIBITON                THERAPEUTICS, INC.** |
|--------|-------------------------------------------------|
|   | (Registrant)                                    |

| Date:                June                19, 2006 | By:                /s/                Henry Fong                                         |
|---------------------------------------------------|------------------------------------------------------------------------------------------|
|                                              | Henry                Fong                                                                |
|                                              | Principal                Executive Officer andPrincipal                Financial Officer |
|                                              |                                                                                     |